 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
Modern online businesses require advanced functionality to compete effectively in the digital marketplace. Experienced WooCommerce website developers play a critical role in building online stores t...
Daily Bulletin
Sydney, Australia, March 14, 2026 , UBlac, the award-winning branding, marketing, and digital innovation company, has officially announced the opening of its new office in Sydney, Australia, marking a...
Daily Bulletin
Construction projects are a heavy reliance on getting the right equipment to the right place, at the right time. Whether you're breaking ground, moving earth, paving roads, or just building, heavy m...
Daily Bulletin
